论文部分内容阅读
[目的]观察醉鱼草苷Ⅳ对H22肝癌小鼠的体内抑瘤作用。[方法]取H22肝癌细胞接种于小鼠右腋皮下,H22肝癌小鼠随机分为5组:模型组、醉鱼草苷Ⅳ高、中、低(1.00、0.50、0.25 mg/kg)3个剂量组和阳性药(CTX,20.0 mg/kg)对照组。每组10只,治疗期间记录各组小鼠的体重变化并观察小鼠生存状态,连续腹腔注射10天后。于第11天观测抑瘤率、脾腺指数、胸腺指数,同时进行血清中SOD、MDA、GGT和AKP含量检测。[结果]与模型组比较,醉鱼草苷Ⅳ高、中剂量组对小鼠H22移植性肝癌均有显著的抑瘤作用(P<0.01),抑瘤率分别为56.96%,50.63%。与模型组相比,醉鱼草苷Ⅳ高剂量组小鼠血清SOD活性增加(P<0.05),醉鱼草苷Ⅳ各剂量组血清MDA、GGT和AKP水平均降低(P<0.01);除SOD活性之外,环磷酰胺组与模型组比较无显著差异。[结论]醉鱼草苷Ⅳ在体内具有抗肝癌作用,其机理可能和机体的抗氧化能力有关系,有待于进一步研究。
[Objective] To observe the anti-tumor effect of Buddleja glycosides Ⅳ in H22 hepatoma mice in vivo. [Method] H22 hepatoma cells were inoculated subcutaneously into the right armpit of mice. H22 hepatoma mice were randomly divided into 5 groups: model group, high, medium and low (1.00,0.50,0.25 mg / kg) Dose group and positive drug (CTX, 20.0 mg / kg) control group. Each group of 10, record the weight changes of mice in each group during treatment and observe the survival status of mice, after continuous intraperitoneal injection of 10 days. On the 11th day, the tumor inhibition rate, spleen gland index and thymus index were observed. Meanwhile, the levels of SOD, MDA, GGT and AKP in serum were detected. [Results] Compared with the model group, the high and middle dose of Buddyroside IV had significant antitumor activity on H22 transplanted hepatoma (P <0.01), and the tumor inhibition rates were 56.96% and 50.63% respectively. Compared with the model group, serum SOD activity of the mice in the high-dose group was significantly increased (P <0.05), and the levels of serum MDA, GGT and AKP were lower in each dose group (P <0.01) SOD activity outside the cyclophosphamide group compared with the model group no significant difference. [Conclusion] Drunkard glycoside IV has anti-hepatocarcinoma effect in vivo, and its mechanism may be related to the antioxidant capacity of the body, which needs further study.